ArticleACS omega2026
Effect of Side Chain Conjugation on the Cytotoxicity and siRNA Transfection Efficiency of 6‑Amino-6-deoxy Curdlan.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cationic curdlan is a promising siRNA delivery platform because it protects siRNA, promotes intracellular siRNA release through charge reduction, prolongs intracellular retention, and supports sustained gene-silencing. However, its relatively high cationic charge can induce cytotoxicity and limit its therapeutic potential. In this study, to reduce toxicity while enhancing siRNA delivery efficiency, we conjugated short ethylene glycol side chains to 6-amino-6-deoxy curdlan and compared the siRNA transfection efficiency of the resulting polymers with that of the parental polymer. Conjugation of ethylene glycol side chains significantly improved both the biocompatibility and in vitro siRNA delivery efficiency, yielding polymers designated MEG1 and MEG2. Notably, conjugation of a short ethylene glycol side chain terminated with a lysine residue (designated CegK1) resulted in markedly enhanced biocompatibility and siRNA delivery efficiency in multiple human glioblastoma cell lines, including U251, U87-MG, and T98G. These findings demonstrate that short ethylene glycol side-chain modification is an effective strategy to optimize cationic curdlan as a safe and efficient siRNA delivery carrier for glioblastoma therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.